Humanigen to Present and Participate at Multiple Investor Events in March
Humanigen, Inc. (NASDAQ: HGEN) announced its participation in multiple investor events in March 2022, focusing on the development of lenzilumab for treating cytokine storm associated with COVID-19. Key events include the Credit Suisse London Global Healthcare Conference (March 1-2), Oppenheimer March Thought Leadership Series (March 4), and the 34th Annual Roth Conference (March 13-15). Management aims to update stakeholders on the company's progress and extend its market reach through these engagements.
- None.
- None.
Details of the events:
Credit Suisse 2022
Date:
Location: Virtual,
Time:
Presenter:
Information: amanda.baird@credit-suisse.com
Oppenheimer March Thought Leadership Series
Date:
Location: Virtual,
Time:
Presenters:
Information: deena.sullivan@opco.com
34th Annual
Date:
Location:
Presentation: Pre-recorded presentations will be available ahead of the conference
Fireside chat:
Participant:
Webcast: https://wsw.com/webcast/roth43/hgen/1810184
Oppenheimer 32nd Annual Healthcare Conference
Date:
Location: Virtual,
Presentation date:
Presentation time:
Participants:
Webcast link: https://wsw.com/webcast/oppenheimer20/hgen/2746044
BIO-Europe Spring 2022
Date:
Location: Virtual,
Presentation: Available on demand
Participants:
Information: www.informaconnect.com/bioeurope-spring
Date:
Location: Virtual
Presentation: Available livestream and on-demand
Participants:
Information: www.medinvestconferences.com
The presentation and webcast links used during the events will be available on the
About
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our plans relating to lenzilumab.
Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections of our latest annual and quarterly reports and other filings with the
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220225005112/en/
Humanigen Investor Relations
tmorris@humanigen.com
+1 650-400-6874
Source:
FAQ
What is Humanigen's focus with lenzilumab?
When is the Credit Suisse London Global Healthcare Conference?
Who will present at Oppenheimer's March Thought Leadership Series?
What is the presentation date for the Oppenheimer 32nd Annual Healthcare Conference?